Evaluation of the impact of a clinical pathway on the progression of acute urinary retention

Neurourol Urodyn. 2019 Jan;38(1):387-392. doi: 10.1002/nau.23873. Epub 2018 Nov 12.

Abstract

Aims: The management of acute urinary retention (AUR) revolves around trial without catheter (TWOC) after prescription of an alpha-blocker. This study evaluates the implementation of a clinical pathway for AUR.

Methods: Specific clinical pathways for AUR was established between the Emergency Department and the Department of Urology in order to reduce the duration of bladder drainage that included standard prescriptions, an information sheet, and a note to be faxed to scheduling nurses to organize the trial without catheter (TWOC). The main endpoint was the reduction in the time between the AUR episode and TWOC, without decreasing urination.

Results: Between April 2015 and December 2016, 248 patients were treated in the Emergency Department, and externally, for AUR. One hundred and seventy patients were enrolled in the pathway group and 78 in the control group. The mean duration of urinary catheterization decreased by 5.5 days as did the number of patients lost to follow-up (32% vs 76%), without decreasing the successful voiding (46% vs 36%). The duration of the urinary catheterization was not related to the chance of successful voiding regardless of the urine volume and a drainage time of over 10 days significantly reduced the chance of success (68%, n = 26 versus 42%, n = 76; P = 0.0038).

Conclusion: The implementation of a clinical pathway for AUR reduced the number of patients lost to follow-up and the catheterization duration, thus optimizing the management of these patients.

Keywords: acute urinary retention; alpha-blocker; catheter removal; clinical pathway; emergency.

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use*
  • Aged
  • Aged, 80 and over
  • Critical Pathways*
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Urinary Catheterization*
  • Urinary Retention / therapy*
  • Urination

Substances

  • Adrenergic alpha-Antagonists